Reduced Radiation Therapy for Oropharyngeal Cancer
Trial Summary
What is the purpose of this trial?
This is a single-arm Phase II study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. The main purpose of this research is to determine the likelihood of cancer growing back in the throat or in the neck two years after completion of radiation if lower doses of radiation are used to a smaller area of the head and neck region than is currently used in standard of care.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for oropharyngeal cancer?
Is reduced radiation therapy for oropharyngeal cancer safe for humans?
Modern radiation therapies like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) are generally safe and can reduce side effects compared to older methods. They help protect normal tissues while effectively treating tumors, leading to fewer complications such as dry mouth and better quality of life.46789
How is reduced radiation therapy unique for treating oropharyngeal cancer?
Reduced radiation therapy, particularly using intensity-modulated radiation therapy (IMRT), is unique because it can target the cancer more precisely, sparing more of the healthy tissue around the tumor. This approach reduces side effects like salivary gland damage while maintaining effective tumor control.2381011
Eligibility Criteria
This trial is for adults over 18 with a specific throat cancer (p16+ oropharyngeal squamous cell carcinoma) that hasn't spread too far. They should be in good physical shape and have no more than four affected lymph nodes. People with very advanced disease, distant spread of cancer, previous head/neck radiation, or more than four positive lymph nodes can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Surgery
Participants undergo Transoral Robotic Surgery (TORS) and neck dissection
Radiation
Participants receive de-intensified adjuvant radiation therapy to the primary site and regional lymphatics
Follow-up
Participants are monitored for safety, effectiveness, and quality of life outcomes after treatment
Treatment Details
Interventions
- Radiation Therapy
Radiation Therapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor